Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 ...

Scottish Land & Estates reveals a bold vision to reshape rural policy, land use and environment for a thriving, future-proofed countryside.

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to ...

The Interleukin-2 (IL-2) market is witnessing rapid growth due to advancements in cancer immunotherapy and autoimmune disease management. IL-2, a vital cytokine, promotes T-cell growth, with therapies ...

Hospital for Special Surgery (HSS) presented a research study at the European Alliance of Associations for Rheumatology ...

Camping bliss is telling ghost stories around a crackling fire as loons call in the distance. Waking up with the birds to ...

Brian Wilson, the Beach Boys' visionary and fragile leader who helped compose and arrange 'Good Vibrations,' 'California Girls' and dozens of other summertime anthems and became one of the world's ...

The vibrant community of SLE extends beyond just its conversational frosh, writes Sherry Xie. It includes dedicated section leaders, guest lecturers, program alums, community connections and ...

Both flare and persistently active disease (PAD) are common disease activity patterns in patients with systemic lupus erythematosus (SLE). A large prospective multinational cohort study, published ...

The terms "disease," "disorder," "condition," and "syndrome ... Understanding the Differences Between These Common Medical Terms. By Cory Martin. Updated on November 13, 2023. ... A systemic ...

There are very few articles in the medical literature that deal with these issues (3-8,12-14,25-27), and the majority focus on the incidence of ovarian failure after cyclophosphamide use. The present ...

In terms of biochemical markers, complement (C) 3 levels increased from 0.63 ± 0.26 g/L at baseline to 0.94 ± 0.21 g/L at 52 weeks, while C4 levels rose from 0.11 ± 0.07 g/L to 0.20 ± 0.08 g/L. The ...